Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 22;9(9):3049.
doi: 10.3390/jcm9093049.

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress

Valentina Gambardella  1   2 , Tania Fleitas  1   2 , Noelia Tarazona  1   2 , Federica Papaccio  1 , Marisol Huerta  1 , Susana Roselló  1 , Francisco Gimeno-Valiente  1 , Desamparados Roda  1   2 , Andrés Cervantes  1
Affiliations
Review

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress

Valentina Gambardella et al. J Clin Med. .

Abstract

Gastroesophageal adenocarcinoma (GEA) represents a heterogeneous disease and, when diagnosed as locally advanced or metastatic, it is characterized by poor prognosis. During the last few years, several molecular classifications have been proposed to try to personalize treatment for those patients diagnosed with advanced disease. Nevertheless, despite the great effort, precision medicine is still far from being a reality. The improvement in the molecular analysis due to the application of high throughput technologies based on DNA and RNA sequencing has opened a novel scenario leading to the personalization of treatment. The possibility to target epidermal growth factor receptor (HER)2, Claudine, Fibroblast Growth Factor Receptors (FGFR), and other alterations with a molecular matched therapy could significantly improve clinical outcomes over advanced gastric cancer patients. On the other hand, the development of immunotherapy could also represent a promising strategy in a selected population. In this review, we sought to describe the novel pathways implicated in GEA progression and the results of the molecular matched therapies.

Keywords: advanced gastric cancer; new drug development; precision medicine.

PubMed Disclaimer

Conflict of interest statement

A.C. declares institutional research funding from Genentech, Merck Serono, BMS, MSD, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas and Fibrogen and advisory board or speaker fees from Merck Serono, Roche, Servier, Takeda and Astellas in the last 5 years. All remaining authors have declared no conflicts of interest.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Nagaraja A.K., Kikuchi O., Bass A.J. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. Cancer Discov. 2019 doi: 10.1158/2159-8290.CD-19-0487. - DOI - PMC - PubMed
    1. Anderson W.F., Rabkin C.S., Turner N., Fraumeni J.F.J., Rosenberg P.S., Camargo M.C. The Changing Face of Noncardia Gastric Cancer Incidence among US Non-Hispanic Whites. J. Natl. Cancer Inst. 2018;110110:608–615. doi: 10.1093/jnci/djx262. - DOI - PMC - PubMed
    1. Lin S.J., Gagnon-bartsch J.A., Tan I.B., Earle S., Ruff L., Pettinger K., Ylstra B., van Grieken N., Rha S.Y., Chung Y.C., et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015;64:1721–1731. doi: 10.1136/gutjnl-2014-308252. - DOI - PMC - PubMed
    1. Cervantes A., Roda D., Tarazona N., Roselló S. Current questions for the treatment of advanced gastric cancer. Cancer Treat. Rev. 2013;3939:60–67. doi: 10.1016/j.ctrv.2012.09.007. - DOI - PubMed